

# Emmanuelle Comets

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6774544/publications.pdf>

Version: 2024-02-01

57  
papers

2,268  
citations

304368

22  
h-index

214527

47  
g-index

57  
all docs

57  
docs citations

57  
times ranked

2816  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ciprofloxacin population pharmacokinetics during long-term treatment of osteoarticular infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2906-2913.	1.3	5
2	The Use of Translational Modelling and Simulation to Develop Immunomodulatory Therapy as an Adjunct to Antibiotic Treatment in the Context of Pneumonia. <i>Pharmaceutics</i> , 2021, 13, 601.	2.0	1
3	Developing Tools to Evaluate Non-linear Mixed Effect Models: 20 Years on the npde Adventure. <i>AAPS Journal</i> , 2021, 23, 75.	2.2	3
4	Conditional Non-parametric Bootstrap for Non-linear Mixed Effect Models. <i>Pharmaceutical Research</i> , 2021, 38, 1057-1066.	1.7	3
5	Taking Kinetic Evaluations of Degradation Data to the Next Level with Nonlinear Mixed-Effects Models. <i>Environments - MDPI</i> , 2021, 8, 71.	1.5	1
6	Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 112053.	2.5	1
7	Effects of Postpartum Supplemental Oral Ca for Dairy Cows Fed Prepartum Dietary Acidogenic Salts. <i>Animals</i> , 2021, 11, 3131.	1.0	2
8	Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 509-514.	1.3	170
9	PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models. <i>Computer Methods and Programs in Biomedicine</i> , 2018, 156, 217-229.	2.6	25
10	Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies. <i>Statistical Methods in Medical Research</i> , 2018, 27, 1860-1877.	0.7	17
11	Recent advances in methodology for clinical trials in small populations: the InSPiRe project. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 186.	1.2	30
12	The Standard Output: A Tool for Agnostic Modeling Storage Format. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 543-546.	1.3	0
13	Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. <i>AAPS Journal</i> , 2017, 19, 727-735.	2.2	16
14	Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations. <i>Biometrical Journal</i> , 2017, 59, 804-825.	0.6	41
15	PharmML in Action: an Interoperable Language for Modeling and Simulation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 651-665.	1.3	6
16	A minimal resting time of 25 min is needed before measuring stabilized blood pressure in subjects addressed for vascular investigations. <i>Scientific Reports</i> , 2017, 7, 12893.	1.6	13
17	Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2695-2708.	1.1	19
18	Model Description Language (MDL): A Standard for Modeling and Simulation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 647-650.	1.3	15

#	ARTICLE	IF	CITATIONS
19	Parameter Estimation in Nonlinear Mixed Effect Models Using <code>saemix</code> , an <i>R</i> Implementation of the SAEM Algorithm. <i>Journal of Statistical Software</i> , 2017, 80, .	1.8	65
20	Variations of hepcidin and iron status parameters during the menstrual cycle in healthy women. <i>British Journal of Haematology</i> , 2016, 175, 980-982.	1.2	21
21	Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1481-1491.	1.4	7
22	Joint Model of Iron and Hepcidin During the Menstrual Cycle in Healthy Women. <i>AAPS Journal</i> , 2016, 18, 490-504.	2.2	19
23	Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates. <i>AAPS Journal</i> , 2015, 17, 597-608.	2.2	5
24	Perinatal exposure to chlordecone and infant growth. <i>Environmental Research</i> , 2015, 142, 123-134.	3.7	24
25	Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 15-33.	0.8	53
26	Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 167-180.	1.1	9
27	A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models. <i>Pharmaceutical Statistics</i> , 2013, 12, 129-140.	0.7	67
28	Pharmacokinetic and Pharmacodynamic Variability of Fluindione in Octogenarians. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 777-786.	2.3	7
29	Why Should Prediction Discrepancies Be Renamed Standardized Visual Predictive Check?. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1284-1285.	1.0	1
30	Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 499-518.	0.8	23
31	Some Alternatives to Asymptotic Tests for the Analysis of Pharmacogenetic Data Using Nonlinear Mixed Effects Models. <i>Biometrics</i> , 2012, 68, 146-155.	0.8	13
32	A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 402-414.	1.1	14
33	Development of a Complex Parent-Metabolite Joint Population Pharmacokinetic Model. <i>AAPS Journal</i> , 2011, 13, 390-404.	2.2	22
34	Evaluation of different tests based on observations for external model evaluation of population analyses. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2010, 37, 49-65.	0.8	72
35	Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4432-4439.	1.4	38
36	Semimechanistic Pharmacokinetic-Pharmacodynamic Model with Adaptation Development for Time-Kill Experiments of Ciprofloxacin against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2379-2384.	1.4	20

#	ARTICLE	IF	CITATIONS
37	The CCGGG insertion/deletion polymorphism of the <i>IRF5</i> promoter is a strong risk factor for primary Sj��gren's syndrome. <i>Arthritis and Rheumatism</i> , 2009, 60, 1991-1997.	6.7	104
38	Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 317-339.	0.8	33
39	A Survey of the Way Pharmacokinetics are Reported in Published Phase I Clinical Trials, with an Emphasis on Oncology. <i>Clinical Pharmacokinetics</i> , 2009, 48, 387-395.	1.6	13
40	Design Optimization in Nonlinear Mixed Effects Models Using Cost Functions: Application to a Joint Model of Infliximab and Methotrexate Pharmacokinetics. <i>Communications in Statistics - Theory and Methods</i> , 2009, 38, 3351-3368.	0.6	7
41	Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R. <i>Computer Methods and Programs in Biomedicine</i> , 2008, 90, 154-166.	2.6	370
42	Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters. <i>Journal of Biopharmaceutical Statistics</i> , 2008, 18, 1084-1102.	0.4	35
43	Are Population Pharmacokinetic and/or Pharmacodynamic Models Adequately Evaluated?. <i>Clinical Pharmacokinetics</i> , 2007, 46, 221-234.	1.6	149
44	Association of an <i>IRF5</i> gene functional polymorphism with Sj��gren's syndrome. <i>Arthritis and Rheumatism</i> , 2007, 56, 3989-3994.	6.7	173
45	Design in nonlinear mixed effects models: Optimization using the Fedorov��Wynn algorithm and power of the Wald test for binary covariates. <i>Statistics in Medicine</i> , 2007, 26, 5162-5179.	0.8	55
46	Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 437-449.	0.8	25
47	Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide. <i>Pharmaceutical Research</i> , 2006, 23, 2036-2049.	1.7	268
48	Norfloxacin Blood-Brain Barrier Transport in Rats Is Not Affected by Probenecid Coadministration. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 371-373.	1.4	6
49	Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 61-71.	1.1	4
50	Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice. <i>British Journal of Pharmacology</i> , 2004, 141, 1214-1222.	2.7	61
51	Comparison of the Pharmacokinetics of S-1, an Oral Anticancer Agent, in Western and Japanese Patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2003, 30, 257-283.	0.8	29
52	Population pharmacodynamic analysis of octreotide in acromegalic patients. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 95-106.	2.3	13
53	EVALUATION OF TESTS BASED ON INDIVIDUAL VERSUS POPULATION MODELING TO COMPARE DISSOLUTION CURVES. <i>Journal of Biopharmaceutical Statistics</i> , 2001, 11, 107-123.	0.4	10
54	Prediction of Fluindione Maintenance Dosage Hampered by Large Intraindividual Variability. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 668-675.	1.0	5

#	ARTICLE	IF	CITATIONS
55	Modeling the Kinetics of Release of Octreotide from Long-Acting Formulations Injected Intramuscularly in Rabbits. <i>Journal of Pharmaceutical Sciences</i> , 2000, 89, 1123-1133.	1.6	12
56	Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 64-78.	2.3	37
57	Modeling INR Data to Predict Maintenance Fluindione Dosage. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 631-639.	1.0	11